At Prostate Cancer Canada, we know that we have been entrusted with a very special mission – to allocate the funds raised by Canadians to programs that support research that will have the greatest potential to improve prostate cancer prevention, diagnosis and treatment and to better manage survivorship. To that end, we employ an equitable, transparent selection process that is free from bias to determine which proposals are funded.
We want to be strategic to ensure we are investing in the absolute best prostate cancer research conducted in this country that is also globally competitive.To do this, we engage leading experts in prostate cancer research to help develop the most effective research programs to allow our outstanding research community to achieve research success.
To ensure that Prostate Cancer Canada funds the best ideas, regardless of the area of specialization or where the research is conducted, each research proposal undergoes a rigorous peer-review process. In this way, high-quality, unbiased reviews by experts determine which research is funded.
Prostate Cancer Canada’s review process applies scientific rigor to decision-making related to research while ensuring the process is lean and efficient. Applicants receive feedback from the review process to help them to best assess their strengths and weaknesses to allow for continued improvement in future applications. Furthermore, PCC takes conflicts of interest between the review panel and applicants very seriously and has enacted measures to address such occurrences.
Review panels comprise prostate cancer researchers from across Canada who collectively represent all areas of the spectrum of prostate cancer research, including biomedical, translational and population health divisions. Additionally, representatives from the non-scientific, patient or survivor community are invited to serve on the review panel and fulfil a crucial role in giving the non-scientific community a voice at the table.